Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2024-08-29 Interim / Quarterly Rep…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Study de-risked by all needed patients passed 6 months, read-out expected in 4-6 weeks
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report' and contains comprehensive financial statements including an Income Statement, Balance Sheet, Cash Flow Statement, and Notes to the Interim Financial Statements for the first half of 2024. It provides detailed operational reviews and financial analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-29 English
Arctic Bioscience - Risikoen redusert i studien da nødvendig antall pasienter har passert 6 måneder, utlesning forventet om 4-6 uker
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report' and contains comprehensive financial statements including an Income Statement, Balance Sheet, Cash Flow Statement, and Notes to the Interim Financial Statements for the first half of 2024. It provides detailed operational reviews and financial analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-29 English
Arctic Bioscience - Study de-risked by all needed patients passed 6 months, read-out expected in 4-6 weeks
Earnings Release Classification · 100% confidence The document provides a summary of financial performance for the first half of 2024 (H1 2024), including revenues, gross profit, adjusted EBITDA, and liquidity. It also discusses operational highlights (clinical trial progress, R&D, sales outlook) and concludes with an announcement of a webcast/Q&A session to present these results. This structure—a summary of period results, management commentary, and an announcement of a presentation—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR), as it focuses on key highlights and financial figures for a half-year period, rather than being the full statutory filing. H1 2024
2024-08-29 English
Arctic Bioscience - Risikoen redusert i studien da nødvendig antall pasienter har passert 6 måneder, utlesning forventet om 4-6 uker
Earnings Release Classification · 100% confidence The document provides a summary of financial performance for the first half of 2024 (H1 2024), including key figures like revenue (NOK 16.7 million), gross profit, and adjusted EBITDA, alongside operational updates on clinical trials (HeROPA study) and business segments (Nutra). It explicitly states financial results for a specific period (H1 2024) and includes forward-looking statements and outlooks. This structure strongly indicates an Earnings Release (ER), which typically contains the key highlights and initial financial figures for a reporting period, rather than the comprehensive details of an Interim Report (IR) or Annual Report (10-K). The mention of a webcast/Q&A session further supports this being the initial announcement of results. H1 2024
2024-08-29 Norwegian
Arctic Bioscience - Invitation to presentation of half year 2024 results
Report Publication Announcement Classification · 98% confidence The document is titled "Arctic Bioscience - Invitation to presentation of half year 2024 results" and explicitly states that the company "will publish its financial results for the first half year of 2024 on Thursday 29[th] of August" and will host a webcast presentation on the same day. This document is an announcement about the upcoming release of results and the associated presentation/Q&A session, not the full financial report itself (which would be an IR) or the transcript of the call (CT). According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces the publication of a report and provides details for an associated event, it fits the description of announcing the release of a report. The closest specific category for announcing the publication/release of a report is 'Report Publication Announcement' (RPA).
2024-08-22 English
Arctic Bioscience - Invitasjon til presentasjon av halvårsresultat for 2024
Report Publication Announcement Classification · 99% confidence The document is an invitation (Invitasjon) announcing the upcoming release of the half-year results (halvårsresultat for 2024) scheduled for August 29th, followed by a webcast presentation and Q&A session. Since the document is short (1836 characters) and its primary function is to announce *when* and *how* the actual financial report presentation will occur, rather than being the report itself (like an IR or 10-K), it fits the definition of a Report Publication Announcement (RPA). It is announcing the publication/presentation of interim results, which aligns best with RPA, although it relates to interim financial data.
2024-08-22 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.